What Mandos Health does

Mandos Health is a clinical-stage biopharmaceutical company developing adrabetadex (VTS-270), an investigational proprietary mixture of 2-hydroxypropyl-β-cyclodextrin isomers that addresses the underlying cholesterol-trafficking defect of Niemann-Pick disease type C (NPC), a rare autosomal-recessive neurodegenerative disorder caused by variants in the NPC1 (~95% of cases) or NPC2 genes. The company operates exclusively in the NPC space under a Public Benefit Corporation structure (Mandos LLC, a wholly-owned subsidiary of Beren Therapeutics P.B.C., headquartered in Thousand Oaks, CA), with a leadership team that collectively holds over 200 years of drug development experience and has been involved with 100+ drug approvals across 17 therapeutic areas. Mandos acquired adrabetadex from Mallinckrodt Pharmaceuticals in 2021, transferred the IND, secured FDA and Health Canada agreements to continue the Expanded Access Program, and has since assembled the largest integrated NPC natural history and registry database (incorporating INPDR, YODA, NIH, and clinical trial data) to support regulatory submissions.

The company submitted a New Drug Application to the FDA in December 2025 for adrabetadex in infantile-onset NPC, supported by Breakthrough Therapy Designation (granted December 9, 2025), Orphan Drug Designation, and Rare Pediatric Disease Designation; an FDA decision is anticipated in Q3 2026 under Priority Review. Its core technology proposition is supported by an externally controlled survival analysis (with up to 11 years of follow-up) showing statistically significant survival improvement in infantile-onset NPC, alongside biomarker evidence of restored cholesterol trafficking (increased 24S-hydroxycholesterol) and reduced neuronal injury markers (decreased FABP3 and calbindin D).

Mandos is pre-commercial: it has no approved product and generates no revenue, instead providing access to adrabetadex through a physician-directed Expanded Access Program now serving 60+ patients across 16+ active treatment sites in the United States and Canada. Its go-to-market is community-led and event-driven, centered on deep engagement with NPC patient advocacy organizations (NNPDF, INPDA, NPUK, Firefly Fund, Parseghian Fund), treating physicians at major academic medical centers, and presence at rare disease and neurology conferences. Future commercialization is envisioned as a specialty pharmaceutical model with government and commercial payer coverage once FDA approval is secured.

Name

Mandos Health

Legal name

Mandos LLC

Website

https://mandoshealth.com

Company type

Private

Founded year

2021

Operating status

Operating

Short description

Mandos Health is a clinical-stage biopharmaceutical company developing adrabetadex (VTS-270), an investigational cyclodextrin-based therapy for Niemann-Pick disease type C (NPC), serving the ultra-rare NPC patient community and their treating physicians through an Expanded Access Program and an NDA filed with the FDA in December 2025.

Ownership category

akta.pro rank

Product category

Rare Disease Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

akta.pro secondary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Rare disease therapeutics
• Cyclodextrin drug development
• Niemann-Pick disease treatment
• Expanded access programs
• Investigational biopharmaceuticals

Headquarters

HQ city

Thousand Oaks

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Expanded Access Program (Pre-Approval): Mandos Health is a pre-commercial biopharmaceutical company developing an investigational drug. Adrabetadex has not been approved by any regulatory authority. EAP provides investigational drug access to eligible patients under regulatory approval; no commercial revenue is generated pre-approval.
2. Future Commercialization (Post-Approval): Upon FDA approval of the NDA (filed December 2025, decision anticipated Q3 2026), Mandos/Beren intends to commercialize adrabetadex for infantile-onset NPC. Revenue model would shift to specialty pharmaceutical commercial model with government and commercial payer coverage.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels7 records

Core offering

Mandos Health develops adrabetadex (VTS-270), a proprietary investigational therapy composed of 2-hydroxypropyl-β-cyclodextrin isomers targeting Niemann-Pick disease type C (NPC) by restoring intracellular cholesterol trafficking. The company also operates an Expanded Access Program (EAP) that supplies adrabetadex to eligible NPC patients under physician supervision at authorized treatment sites, while advancing the drug through regulatory review (NDA submitted December 2025; FDA decision anticipated Q3 2026).

Product overview

Mandos Health is a biopharmaceutical company focused on developing adrabetadex (VTS-270), an investigational cyclodextrin-based therapy for Niemann-Pick disease type C (NPC). The company operates through two key offerings: the core investigational drug adrabetadex, which targets the underlying cholesterol trafficking defect in NPC, and the Expanded Access Program (EAP), which provides ongoing patient access to the therapy. Mandos acquired adrabetadex from Mallinckrodt in 2021 and has submitted an NDA to the FDA for approval in infantile-onset NPC.

Differentiator

Problem solved

Functional benefit

Products and services

• Adrabetadex (VTS-270) Proprietary investigational mixture of 2-hydroxypropyl-β-cyclodextrin isomers in development for the treatment of Niemann-Pick disease type C (NPC) by re-establishing intracellular cholesterol trafficking. Administered intrathecally and/or intravenously to NPC patients under physician supervision. NDA submitted to FDA in December 2025 with Breakthrough Therapy Designation; FDA decision anticipated Q3 2026.
• Expanded Access Program (EAP) for Adrabetadex Regulatory-approved program providing investigational adrabetadex to NPC patients with serious or life-threatening disease who cannot participate in ongoing clinical trials. Operates through licensed NPC-treating physicians at authorized sites in the United States (FDA-authorized) and Canada (Health Canada SAP). Enrolled over 60 patients across 16+ active sites in North America as of 2026.

Quantifiable outcome

• Statistically significant improvement in overall survival in infantile-onset NPC patients (neurological onset before 6 years) treated with intrathecal adrabetadex compared to matched external controls from 4 major disease databases/publications
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature4 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• RoquettecoreStrategic or Co-development Partner · 23 May 2023Roquette, a family-owned global leader in plant-based ingredients and pharmaceutical excipients (operating in 100+ countries, ~5 billion euros turnover, 8,000+ employees), entered a strategic investment and innovation agreement with Beren Therapeutics P.B.C. (Mandos' parent company) to expand the full potential of Beren's cyclodextrin technologies and medicinal applications. The partnership includes collaboration on chemistry, manufacturing, controls (CMC) management, advancing safety protocols, and regulatory registration. Both companies' missions align around pushing boundaries of scientific innovation for efficient and sustainable manufacturing processes.
• INPDR Gateway LtdcoreStrategic or Co-development Partner · 1 January 2023Partnership struck in January 2023 to gain access to the INPDR (International Niemann-Pick Disease Registry) patient registry. Mandos accesses real-world data from more than 300 NPC patients, providing evidence to accelerate research. The collaboration integrates registry data with Mandos' clinical trial and natural history data as part of the most comprehensive NPC analysis to date. Press release via Business Wire June 16, 2023.
• Rush University Medical CentercoreStrategic or Co-development PartnerLead EAP investigator site led by Dr. Elizabeth Berry-Kravis, Professor of Pediatrics and Director of RUSH Pediatric Neurosciences F.A.S.T. Center. Dr. Berry-Kravis served as principal investigator for the EAP and lead study author for the landmark externally controlled survival analysis presented at ANA 2025 and CNS 2025, demonstrating statistically significant survival benefit in infantile-onset NPC patients treated with adrabetadex.
• National Institutes of Health (NIH)coreStrategic or Co-development PartnerDr. Forbes D. Porter from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH, led the early Phase 1 and Phase 2 clinical trials for adrabetadex. Dr. Porter's team provided natural history data supporting the externally controlled survival analysis included in the NDA. NIH biomarker data (decreased neuronal damage markers) presented at CNS 2025 further supporting adrabetadex's disease-modifying potential.
• National Niemann-Pick Disease Foundation (NNPDF)coreGTM or Marketing PartnerMandos maintains a close partnership with NNPDF for equitable community communication, conference co-sponsorship (annual Family Support & Medical Conference), and patient advocacy. Mandos participates in NNPDF conferences, shares news simultaneously with the full NPC community, and conducted a joint webinar with NNPDF in January 2026. EAP resources shared through NNPDF website.
• International Niemann-Pick Disease Alliance (INPDA)coreGTM or Marketing PartnerMandos attends and sponsors the annual INPDA conference (including INPDA Face to Face meeting in Tarragona, Spain November 2023, and INPDA Annual Meeting in Argentina September 2025). Partnership focuses on global NPC community engagement, awareness, and equitable information dissemination. Mandos presented data at the INPDA Annual Meeting in Argentina September 18-21, 2025.
• Beren Therapeutics Public Benefit Corporation (P.B.C.)coreStrategic or Co-development PartnerMandos LLC is a wholly-owned subsidiary of Beren Therapeutics P.B.C., a founder-led, clinical-stage biotechnology company pioneering cyclodextrin-based therapeutics for cholesterol trafficking diseases. Beren acquired adrabetadex from Mallinckrodt in 2021 and established Mandos to operate as the patient-facing subsidiary focused on NPC. Beren is headquartered in Thousand Oaks, CA. Roquette partnership announced with Beren in May 2023 for cyclodextrin innovation.
• Ara Parseghian Medical Research FoundationcoreGTM or Marketing PartnerMandos supports the Ara Parseghian Medical Research Foundation's annual NPC scientific conference (June 8-11, 2024 Tucson, AZ; June 10-13, 2023 Tucson, AZ). Conference theme 'HOPE WINS' creates forum for NPC patients, families, communities, non-profits, and industry. Mandos presents data and engages with key opinion leaders and the community.
• Niemann-Pick UK (NPUK)minorGTM or Marketing PartnerMandos attended NPUK Annual Family Conference & Interactive Workshop on Niemann-Pick Diseases 2022 in Bedfordshire, England. Partnership supports UK NPC community engagement and awareness efforts.
• YODA Project (Yale Open Data Access)coreStrategic or Co-development PartnerMandos gained access to YODA Project data as part of its natural history data gathering initiative. YODA data integrated with INPDR registry, NIH data, and clinical trial data as part of the largest NPC natural history database ever assembled, supporting regulatory submissions.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Alexion (AstraZeneca Rare Disease): Alexion pioneered rare-disease commercial franchises (Soliris, Strensiq) and was acquired by AstraZeneca for $39B. Comparable to Mandos as a specialty ultra-rare-disease commercial benchmark, though at vastly greater scale. The relevant comparison is on patient-finding, EAP-to-launch conversion, and orphan pricing benchmarks.
• BioMarin Pharmaceutical: BioMarin is an established rare-disease specialty biotech with a portfolio spanning enzyme replacement, gene therapy, and small molecules for ultra-rare disorders including CNS conditions. Directly comparable to Mandos as a benchmark for ultra-rare launch economics, orphan pricing, and franchise expansion strategy.
• Ultragenyx Pharmaceutical: Ultragenyx is a commercial-stage rare-disease biotech with multiple approved products for genetic and metabolic disorders (including neurology-focused programs). Comparable to Mandos in business model — multi-asset rare-disease developer with experience in orphan regulatory pathways and ultra-rare commercial launches.
• Takeda Pharmaceutical (via Shire acquisition): Takeda's $62B Shire acquisition created one of the largest rare-disease franchises globally. Comparable to Mandos as a benchmark for how rare-disease pipelines can be acquired, scaled, and integrated — relevant since Beren/Mandos itself represents a focused rare-disease asset.

Direct peers

• Cyclo Therapeutics: Cyclo Therapeutics develops Trappsol Cyclo, a cyclodextrin-based therapy also targeting Niemann-Pick disease type C — directly comparable to Mandos' adrabetadex (VTS-270) because both pursue the same NPC mechanism with chemically related cyclodextrin platforms. Their Phase 3 NPC program provides a competitive benchmark and shapes FDA expectations for the class.

Others

• Pfizer: Pfizer is one of the largest pharmaceutical companies with rare-disease and neurology franchises and has historically been an active acquirer of late-stage rare-disease assets. Relevant to Mandos as a potential strategic acquirer or commercial partner for global launch beyond North America.
• Mallinckrodt Pharmaceuticals: Mallinckrodt was the previous sponsor of adrabetadex (VTS-270) prior to Mandos' 2021 acquisition. Comparable as a specialty-pharma historical owner of the same asset; relevant for understanding the prior clinical-hold history and the BTD rescission in 2016, but not a current competitive peer.
• Genentech (Roche): Roche/Genentech operates a large neurology and rare-disease portfolio (including spinal muscular atrophy and genetic disorder programs). Comparable to Mandos as a potential acquirer of late-stage rare-disease assets and as a benchmark for CNS/ultra-rare neurology franchise economics.

Emerging players

• Zevra Therapeutics: Zevra Therapeutics (formerly Orphazyme/KemPharm) developed arimoclomol for NPC and other rare neurological diseases. Although arimoclomol's initial NPC path encountered FDA challenges, Zevra is a directly comparable small rare-disease biotech navigating regulatory pathways in the same NPC indication space.
• IntraBio: IntraBio is a clinical-stage rare-disease biopharmaceutical company developing therapies for lysosomal storage and neurodegenerative disorders including NPC. Comparable to Mandos as a focused rare-disease developer pursuing NPC and adjacent indications with similar regulatory milestones (Orphan Drug, EAP pathways).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mandos-health

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mandos Health